Condition (MeSH)
Vascular Neoplasms
ClinicalTrials.gov lists 6 trials for Vascular Neoplasms or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
6 of the 6 trials are tagged with Vascular Neoplasms itself; the rest are tagged with a narrower condition beneath it.
When did Vascular Neoplasms trials start? (4)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 4
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2023 | 1 |
| 2020 | 2 |
| 2016 | 2 |
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Vascular Neoplasms trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 2 |
| Phase 4 | 1 |
| Not applicable | 1 |
| Observational | 2 |
How many Vascular Neoplasms trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Active, not recruiting | 2 |
| Completed | 3 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Vascular Neoplasms trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Fluidx Medical Technology, Inc. | 1 |
| National Eye Institute (NEI) | 1 |
Which serious adverse events do Vascular Neoplasms trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Abdominal pain | 10 | 2 |
| Dyspnea | 8 | 2 |
| Fever | 7 | 2 |
| Lung infection | 7 | 2 |
| Pleural effusion | 7 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Vascular Neoplasms? (35)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Treatment of superficial benign vascular tumors by high intensity focused ultrasound: Observations in two illustrative cases. | Journal of cosmetic dermatology | 2022 | Yes |
| Long-term outcomes following en bloc resection for pancreatic ductal adenocarcinoma of the head with portomesenteric venous invasion. | Asian journal of surgery | 2021 | Yes |
| Adjuvant transarterial chemoembolization after curative hepatectomy for hepatocellular carcinoma with microvascular invasion: A systematic review and meta-analysis. | Clinics and research in hepatology and gastroenterology | 2020 | Yes |
| 18F-FDG PET/CT predicts microvascular invasion and early recurrence after liver resection for hepatocellular carcinoma: A prospective observational study. | HPB : the official journal of the International Hepato Pancreato Biliary Association | 2019 | Yes |
| Up-to-date imaging review of paediatric soft tissue vascular masses, focusing on sonography. | La Radiologia medica | 2019 | Yes |
Showing 5 of 35 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.